Kilitch Drugs (India) Limited (BOM:524500)
India
· Delayed Price · Currency is INR 320.10
+1.50 (0.47%)
At close: Mar 9, 2026
Kilitch Drugs (India) Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Revenue | 2,071 | 1,983 | 1,544 | 1,396 | 1,142 | 685.23 | Upgrade
|
| Revenue Growth (YoY) | 13.85% | 28.47% | 10.58% | 22.20% | 66.71% | 28.51% | Upgrade
|
| Cost of Revenue | 1,114 | 1,053 | 793.92 | 754.16 | 673.86 | 379.13 | Upgrade
|
| Gross Profit | 956.89 | 930.05 | 749.8 | 641.83 | 468.49 | 306.11 | Upgrade
|
| Selling, General & Admin | 355.01 | 312.74 | 239.66 | 231.58 | 117.14 | 97.23 | Upgrade
|
| Other Operating Expenses | 307.54 | 302.66 | 262.1 | 234.61 | 234.96 | 156.1 | Upgrade
|
| Operating Expenses | 689.01 | 638.08 | 526.82 | 493.27 | 368.33 | 264.76 | Upgrade
|
| Operating Income | 267.87 | 291.97 | 222.98 | 148.56 | 100.16 | 41.34 | Upgrade
|
| Interest Expense | -57.18 | -50.41 | -59.29 | -49.19 | -11.98 | -7.54 | Upgrade
|
| Interest & Investment Income | 36 | 36 | 4.2 | 3.1 | 2.5 | 2.26 | Upgrade
|
| Earnings From Equity Investments | 0 | 0 | 0.02 | 0.02 | -0.02 | -0.02 | Upgrade
|
| Currency Exchange Gain (Loss) | 28.07 | 28.07 | 19.96 | 15.6 | -2.29 | 9.76 | Upgrade
|
| Other Non Operating Income (Expenses) | 20.76 | 7.93 | 0.22 | 0.59 | 2.62 | 1.8 | Upgrade
|
| EBT Excluding Unusual Items | 295.53 | 313.57 | 188.09 | 118.69 | 90.98 | 47.59 | Upgrade
|
| Impairment of Goodwill | -8.43 | -8.43 | -8.43 | -8.43 | -8.43 | -8.43 | Upgrade
|
| Gain (Loss) on Sale of Investments | 39.6 | 39.6 | 13.89 | 9.88 | 13.59 | 12.03 | Upgrade
|
| Pretax Income | 326.71 | 344.74 | 193.55 | 120.14 | 96.14 | 51.2 | Upgrade
|
| Income Tax Expense | 74.52 | 95.34 | 57.79 | 37.32 | 34.01 | 13.53 | Upgrade
|
| Earnings From Continuing Operations | 252.19 | 249.4 | 135.75 | 82.83 | 62.14 | 37.67 | Upgrade
|
| Minority Interest in Earnings | 12.11 | 17.61 | 10.26 | 21.65 | 11.54 | -0.96 | Upgrade
|
| Net Income | 264.3 | 267.01 | 146.01 | 104.48 | 73.67 | 36.71 | Upgrade
|
| Net Income to Common | 264.3 | 267.01 | 146.01 | 104.48 | 73.67 | 36.71 | Upgrade
|
| Net Income Growth | 35.45% | 82.86% | 39.75% | 41.82% | 100.68% | 336.00% | Upgrade
|
| Shares Outstanding (Basic) | 17 | 16 | 16 | 16 | 16 | 15 | Upgrade
|
| Shares Outstanding (Diluted) | 17 | 16 | 16 | 16 | 16 | 15 | Upgrade
|
| Shares Change (YoY) | 3.10% | 0.96% | 2.23% | 0.10% | 0.56% | 0.37% | Upgrade
|
| EPS (Basic) | 15.95 | 16.60 | 9.17 | 6.71 | 4.73 | 2.37 | Upgrade
|
| EPS (Diluted) | 15.94 | 16.60 | 9.17 | 6.71 | 4.73 | 2.37 | Upgrade
|
| EPS Growth | 31.36% | 81.10% | 36.71% | 41.76% | 99.58% | 334.09% | Upgrade
|
| Free Cash Flow | - | -293.31 | -79.85 | -12.26 | -24.19 | 93.61 | Upgrade
|
| Free Cash Flow Per Share | - | -18.24 | -5.01 | -0.79 | -1.55 | 6.05 | Upgrade
|
| Gross Margin | 46.20% | 46.90% | 48.57% | 45.98% | 41.01% | 44.67% | Upgrade
|
| Operating Margin | 12.93% | 14.72% | 14.44% | 10.64% | 8.77% | 6.03% | Upgrade
|
| Profit Margin | 12.76% | 13.46% | 9.46% | 7.48% | 6.45% | 5.36% | Upgrade
|
| Free Cash Flow Margin | - | -14.79% | -5.17% | -0.88% | -2.12% | 13.66% | Upgrade
|
| EBITDA | 288.13 | 313.56 | 246.36 | 175.51 | 116.29 | 52.75 | Upgrade
|
| EBITDA Margin | 13.91% | 15.81% | 15.96% | 12.57% | 10.18% | 7.70% | Upgrade
|
| D&A For EBITDA | 20.25 | 21.59 | 23.38 | 26.96 | 16.13 | 11.41 | Upgrade
|
| EBIT | 267.87 | 291.97 | 222.98 | 148.56 | 100.16 | 41.34 | Upgrade
|
| EBIT Margin | 12.93% | 14.72% | 14.44% | 10.64% | 8.77% | 6.03% | Upgrade
|
| Effective Tax Rate | 22.81% | 27.66% | 29.86% | 31.06% | 35.37% | 26.43% | Upgrade
|
| Revenue as Reported | 2,195 | 2,095 | 1,589 | 1,425 | 1,171 | 711.91 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.